Suppr超能文献

年龄相对于放射性碘摄取率在伴远处转移的分化型甲状腺癌中作为预后因素的重要性。

The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.

作者信息

Mihailovic Jasna, Stefanovic Ljubomir, Malesevic Milica, Markoski Branko

机构信息

Center of Nuclear Medicine, Oncology Institute of Vojvodina , Sremska Kamenica, Serbia.

出版信息

Thyroid. 2009 Mar;19(3):227-32. doi: 10.1089/thy.2008.0186.

Abstract

BACKGROUND

Differentiated thyroid carcinoma (DTC) usually has a good prognosis and rarely develops distant metastases. Although it might be expected that avid radioiodine uptake in distant metastases would be associated with a favorable outcome, there are few long-term studies regarding this. The present study was performed to evaluate the influence of radioiodine uptake in distant metastases on the disease-specific survival (DSS) in DTC patients.

METHODS

This retrospective study included 77 DTC patients with distant metastases (M1) who were treated with (131)I therapy from 1977 to the end of 2000 in our institution. The median follow-up of patients was 6.1 years. Univariate and multivariate analysis were performed using the Kaplan-Meier method and log rank test, and Cox Regression model, respectively.

RESULTS

Seventy-seven patients with M1 included 51 (66.2%) women and 26 (33.8%) men; 32 (41.6%) patients were <45 years old and 45 (58.4%) patients were >or=45 years old (range: 8-70 years; mean age: 45.4 years); histologically, there were 54 (70.1%) papillary carcinomas, 22 (28.6%) follicular carcinomas, and one case (1.3%) with an inconclusive histological report. The probability of DSS after appearance of M1 was 57.95% after 5 years, 48.31% after 10 years, and 39.46% after 15 and 20 years. In patients with iodine-avid distant metastases the 5-year DSS was 66.54%, the 10-year DSS was 55.09%, and the 15- and 20-year DSS were 44.99%. In contrast, patients with non-iodine-avid lesions had a 5- and 10-year DSS of 18.33%. This difference relating to the relationship between (131)I uptake in distant metastases and survival was significant (p = 0.0006). The proportion of patients with non-iodine-avid distant metastases that were >or=45 years old was significantly greater than the proportion of patients with non-iodine-avid distant metastases that were <45 years old (p < 0.01). If patients were matched for age, iodine non-avidity significantly shortened the survival in patients <45 years old (p < 0.001). According to multivariate analysis age had significantly greater influence on survival compared with iodine avidity (p < 0.001, p = 0.078, respectively).

CONCLUSION

Patients with distant metastases have a long-term survival that depends, in addition to other factors, on age and the degree of radioiodine uptake in distant metastases.

摘要

背景

分化型甲状腺癌(DTC)通常预后良好,很少发生远处转移。虽然预期远处转移灶中放射性碘摄取与良好预后相关,但关于此的长期研究较少。本研究旨在评估远处转移灶中放射性碘摄取对DTC患者疾病特异性生存(DSS)的影响。

方法

这项回顾性研究纳入了1977年至2000年底在我院接受(131)I治疗的77例有远处转移(M1)的DTC患者。患者的中位随访时间为6.1年。分别采用Kaplan-Meier法和对数秩检验以及Cox回归模型进行单因素和多因素分析。

结果

77例M1患者中,女性51例(66.2%),男性26例(33.8%);32例(41.6%)患者年龄<45岁,45例(58.4%)患者年龄≥45岁(范围:8 - 70岁;平均年龄:45.4岁);组织学上,有54例(70.1%)乳头状癌,22例(28.6%)滤泡状癌,1例(1.3%)组织学报告不明确。M1出现后的DSS概率在5年后为57.95%,10年后为48.31%,15年和20年后为39.46%。有碘摄取的远处转移患者5年DSS为66.54%,10年DSS为55.09%,15年和20年DSS为44.99%。相比之下,无碘摄取病变患者的5年和10年DSS为18.33%。远处转移灶中(131)I摄取与生存之间的这种差异具有统计学意义(p = 0.0006)。年龄≥45岁的无碘摄取远处转移患者比例显著高于年龄<45岁的无碘摄取远处转移患者比例(p < 0.01)。如果按年龄匹配患者,无碘摄取显著缩短了<45岁患者的生存时间(p < 0.001)。根据多因素分析,年龄对生存的影响显著大于碘摄取情况(分别为p < 0.001,p = 0.078)。

结论

有远处转移的患者长期生存除其他因素外,还取决于年龄和远处转移灶中放射性碘摄取程度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验